Business Description
Annji Pharmaceutical Co Ltd
ISIN : TW0007754004
Description
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.35 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 5.88 | |||||
| Beneish M-Score | 74.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.93 | |||||
| 9-Day RSI | 50.94 | |||||
| 14-Day RSI | 46.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.04 | |||||
| Quick Ratio | 4.04 | |||||
| Cash Ratio | 3.85 | |||||
| Days Sales Outstanding | 0.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -20.86 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 12.85 | |||||
| Operating Margin % | -187.15 | |||||
| Net Margin % | -229.37 | |||||
| FCF Margin % | -55.44 | |||||
| ROE % | -45.87 | |||||
| ROA % | -37.64 | |||||
| ROIC % | -91.43 | |||||
| ROC (Joel Greenblatt) % | -613.25 | |||||
| ROCE % | -38.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 23.43 | |||||
| PB Ratio | 3.64 | |||||
| Price-to-Tangible-Book | 4.25 | |||||
| EV-to-EBIT | -9.03 | |||||
| EV-to-EBITDA | -10.39 | |||||
| EV-to-Revenue | 18.25 | |||||
| EV-to-FCF | -31.93 | |||||
| Price-to-Net-Current-Asset-Value | 5.29 | |||||
| Price-to-Net-Cash | 5.66 | |||||
| Earnings Yield (Greenblatt) % | -11.08 | |||||
| FCF Yield % | -2.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Annji Pharmaceutical Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 143.53 | ||
| EPS (TTM) (NT$) | -4.25 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 46.64 | ||
| 14-Day ATR (NT$) | 1.41075 | ||
| 20-Day SMA (NT$) | 36.04 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (NT$) | 34 - 72.4 | ||
| Shares Outstanding (Mil) | 93.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Annji Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Annji Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Annji Pharmaceutical Co Ltd Frequently Asked Questions
What is Annji Pharmaceutical Co Ltd(ROCO:7754)'s stock price today?
The current price of ROCO:7754 is NT$35.95. The 52 week high of ROCO:7754 is NT$72.40 and 52 week low is NT$34.00.
When is next earnings date of Annji Pharmaceutical Co Ltd(ROCO:7754)?
The next earnings date of Annji Pharmaceutical Co Ltd(ROCO:7754) is .
Does Annji Pharmaceutical Co Ltd(ROCO:7754) pay dividends? If so, how much?
Annji Pharmaceutical Co Ltd(ROCO:7754) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers